Staar Surgical Co. Reaches New 12-Month High at $13.57 (STAA)
Staar Surgical (NASDAQ:STAA)’s share price reached a new 52-week high during trading hours on Monday, AR Network reports. The company traded as high as $13.57 and last traded at $13.53, with a volume of 107,740 shares trading hands. The stock had previously closed at $13.15.
A number of analysts have recently weighed in on STAA shares. Analysts at Benchmark Co. initiated coverage on shares of Staar Surgical (NASDAQ:STAA) in a research note to investors on Tuesday, September 10th. They set a “buy” rating and a $15.00 price target on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Staar Surgical (NASDAQ:STAA) from $6.50 to $10.00 in a research note to investors on Thursday, August 1st. Finally, analysts at Zacks downgraded shares of Staar Surgical (NASDAQ:STAA) from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, July 10th. They now have a $11.50 price target on the stock. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Staar Surgical currently has an average rating of “Buy” and a consensus target price of $12.17.
Staar Surgical has a one year low of $4.99 and a one year high of $13.45. The stock has a 50-day moving average of $12.35 and a 200-day moving average of $9.50. The company’s market cap is $500.8 million.
Staar Surgical (NASDAQ:STAA) last released its earnings data on Wednesday, July 31st. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.01. The company had revenue of $18.20 million for the quarter, compared to the consensus estimate of $17.40 million. During the same quarter in the previous year, the company posted $0.03 earnings per share. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. Analysts expect that Staar Surgical will post $0.09 EPS for the current fiscal year.
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye. The Company is the maker of lenses used worldwide in corrective or refractive surgery.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.